Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 131 entries
Sorted by: Best Match Show Resources per page
The Myxobacterium .

Frontiers in microbiology

Lloyd DG, Whitworth DE.
PMID: 28352265
Front Microbiol. 2017 Mar 14;8:439. doi: 10.3389/fmicb.2017.00439. eCollection 2017.

The myxobacterium

Cite
Lloyd DG, Whitworth DE. The Myxobacterium . Front Microbiol. 2017;8:439doi: 10.3389/fmicb.2017.00439.
Lloyd, D. G., & Whitworth, D. E. (2017). The Myxobacterium . Frontiers in microbiology, 8439. https://doi.org/10.3389/fmicb.2017.00439
Lloyd, Daniel G, and Whitworth, David E. "The Myxobacterium ." Frontiers in microbiology vol. 8 (2017): 439. doi: https://doi.org/10.3389/fmicb.2017.00439
Lloyd DG, Whitworth DE. The Myxobacterium . Front Microbiol. 2017 Mar 14;8:439. doi: 10.3389/fmicb.2017.00439. eCollection 2017. PMID: 28352265; PMCID: PMC5348527.
Copy Download .nbib Format: NLM
SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity.

Molecular genetics & genomic medicine

Casey RT, Ascher DB, Rattenberry E, Izatt L, Andrews KA, Simpson HL, Challis B, Park SM, Bulusu VR, Lalloo F, Pires DEV, West H, Clark GR, Smith PS, Whitworth J, Papathomas TG, Taniere P, Savisaar R, Hurst LD, Woodward ER, Maher ER.
PMID: 28546994
Mol Genet Genomic Med. 2017 Mar 02;5(3):237-250. doi: 10.1002/mgg3.279. eCollection 2017 May.

PURPOSE: To evaluate the role of germline PATIENTS AND METHODS: A systematic literature review and a retrospective review of the molecular and clinical features of patients identified with putative germline variants in UK molecular genetic laboratories was performed. To...

Cite
Casey RT, Ascher DB, Rattenberry E, et al. SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity. Mol Genet Genomic Med. 2017;5(3):237-250doi: 10.1002/mgg3.279.
Casey, R. T., Ascher, D. B., Rattenberry, E., Izatt, L., Andrews, K. A., Simpson, H. L., Challis, B., Park, S. M., Bulusu, V. R., Lalloo, F., Pires, D. E. V., West, H., Clark, G. R., Smith, P. S., Whitworth, J., Papathomas, T. G., Taniere, P., Savisaar, R., Hurst, L. D., Woodward, E. R., & Maher, E. R. (2017). SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity. Molecular genetics & genomic medicine, 5(3), 237-250. https://doi.org/10.1002/mgg3.279
Casey, Ruth T, et al. "SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity." Molecular genetics & genomic medicine vol. 5,3 (2017): 237-250. doi: https://doi.org/10.1002/mgg3.279
Casey RT, Ascher DB, Rattenberry E, Izatt L, Andrews KA, Simpson HL, Challis B, Park SM, Bulusu VR, Lalloo F, Pires DEV, West H, Clark GR, Smith PS, Whitworth J, Papathomas TG, Taniere P, Savisaar R, Hurst LD, Woodward ER, Maher ER. SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity. Mol Genet Genomic Med. 2017 Mar 02;5(3):237-250. doi: 10.1002/mgg3.279. eCollection 2017 May. PMID: 28546994; PMCID: PMC5441402.
Copy Download .nbib Format: NLM
Synergism Between Bacterial GAPDH and OMVs: Disparate Mechanisms but Co-Operative Action.

Frontiers in microbiology

Whitworth DE, Morgan BH.
PMID: 26617577
Front Microbiol. 2015 Nov 09;6:1231. doi: 10.3389/fmicb.2015.01231. eCollection 2015.

No abstract available.

Cite
Whitworth DE, Morgan BH. Synergism Between Bacterial GAPDH and OMVs: Disparate Mechanisms but Co-Operative Action. Front Microbiol. 2015;6:1231doi: 10.3389/fmicb.2015.01231.
Whitworth, D. E., & Morgan, B. H. (2015). Synergism Between Bacterial GAPDH and OMVs: Disparate Mechanisms but Co-Operative Action. Frontiers in microbiology, 61231. https://doi.org/10.3389/fmicb.2015.01231
Whitworth, David E, and Morgan, Bethan H. "Synergism Between Bacterial GAPDH and OMVs: Disparate Mechanisms but Co-Operative Action." Frontiers in microbiology vol. 6 (2015): 1231. doi: https://doi.org/10.3389/fmicb.2015.01231
Whitworth DE, Morgan BH. Synergism Between Bacterial GAPDH and OMVs: Disparate Mechanisms but Co-Operative Action. Front Microbiol. 2015 Nov 09;6:1231. doi: 10.3389/fmicb.2015.01231. eCollection 2015. PMID: 26617577; PMCID: PMC4637417.
Copy Download .nbib Format: NLM
Assessing outcomes of health and medical research: do we measure what counts or count what we can measure?.

Australia and New Zealand health policy

Wells R, Whitworth JA.
PMID: 17597545
Aust New Zealand Health Policy. 2007 Jun 28;4:14. doi: 10.1186/1743-8462-4-14.

Governments world wide are increasingly demanding outcome measures to evaluate research investment. Health and medical research outputs can be considered as gains in knowledge, wealth and health. Measurement of the impacts of research on health are difficult, particularly within...

Cite
Wells R, Whitworth JA. Assessing outcomes of health and medical research: do we measure what counts or count what we can measure?. Aust New Zealand Health Policy. 2007;4:14doi: 10.1186/1743-8462-4-14.
Wells, R., & Whitworth, J. A. (2007). Assessing outcomes of health and medical research: do we measure what counts or count what we can measure?. Australia and New Zealand health policy, 414. https://doi.org/10.1186/1743-8462-4-14
Wells, Robert, and Whitworth, Judith A. "Assessing outcomes of health and medical research: do we measure what counts or count what we can measure?." Australia and New Zealand health policy vol. 4 (2007): 14. doi: https://doi.org/10.1186/1743-8462-4-14
Wells R, Whitworth JA. Assessing outcomes of health and medical research: do we measure what counts or count what we can measure?. Aust New Zealand Health Policy. 2007 Jun 28;4:14. doi: 10.1186/1743-8462-4-14. PMID: 17597545; PMCID: PMC1929109.
Copy Download .nbib Format: NLM
Competition in health research: the experience of the John Curtin School of Medical Research.

Australia and New Zealand health policy

Whitworth JA.
PMID: 15771773
Aust New Zealand Health Policy. 2005 Mar 16;2(1):5. doi: 10.1186/1743-8462-2-5.

BACKGROUND: In 2002 the Australian National Competitive Grants System was opened to the Institute of Advanced Studies at the Australian National University as part of a commitment to transparency, competitiveness, and collaboration in national research funding. RESULTS: The block...

Cite
Whitworth JA. Competition in health research: the experience of the John Curtin School of Medical Research. Aust New Zealand Health Policy. 2005;2(1):5doi: 10.1186/1743-8462-2-5.
Whitworth, J. A. (2005). Competition in health research: the experience of the John Curtin School of Medical Research. Australia and New Zealand health policy, 2(1), 5. https://doi.org/10.1186/1743-8462-2-5
Whitworth, Judith A. "Competition in health research: the experience of the John Curtin School of Medical Research." Australia and New Zealand health policy vol. 2,1 (2005): 5. doi: https://doi.org/10.1186/1743-8462-2-5
Whitworth JA. Competition in health research: the experience of the John Curtin School of Medical Research. Aust New Zealand Health Policy. 2005 Mar 16;2(1):5. doi: 10.1186/1743-8462-2-5. PMID: 15771773; PMCID: PMC555854.
Copy Download .nbib Format: NLM
XX germ cells: the difference between an ovary and a testis.

Trends in endocrinology and metabolism: TEM

Whitworth DJ.
PMID: 18406227
Trends Endocrinol Metab. 1998 Jan-Feb;9(1):2-6. doi: 10.1016/s1043-2760(98)00002-2.

In mammals, gonadal sex is determined by the action of the testis-determining gene, SRY. In the absence of SRY, the indifferent gonad follows an alternative pathway and develops as an ovary. Both mitotic and meiotic germ cells appear to...

Cite
Whitworth DJ. XX germ cells: the difference between an ovary and a testis. Trends Endocrinol Metab. 1998;9(1):2-6doi: 10.1016/s1043-2760(98)00002-2.
Whitworth, D. J. (1998). XX germ cells: the difference between an ovary and a testis. Trends in endocrinology and metabolism: TEM, 9(1), 2-6. https://doi.org/10.1016/s1043-2760(98)00002-2
Whitworth, D J. "XX germ cells: the difference between an ovary and a testis." Trends in endocrinology and metabolism: TEM vol. 9,1 (1998): 2-6. doi: https://doi.org/10.1016/s1043-2760(98)00002-2
Whitworth DJ. XX germ cells: the difference between an ovary and a testis. Trends Endocrinol Metab. 1998 Jan-Feb;9(1):2-6. doi: 10.1016/s1043-2760(98)00002-2. PMID: 18406227.
Copy Download .nbib Format: NLM
Spina bifida occulta as a relative contraindication for percutaneous retrograde lead insertion for sacral nerve root stimulation.

Neuromodulation : journal of the International Neuromodulation Society

Michael LM, Whitworth LA, Feler CA.
PMID: 22151780
Neuromodulation. 2002 Jan;5(1):38-40. doi: 10.1046/j.1525-1403.2002._2007.x.

Percutaneous retrograde lead insertion for sacral nerve root stimulation is a newly described technique being applied to a variety of pain disorders. The success of the procedure rests in a defined epidural space such that there is unimpeded progression...

Cite
Michael LM, Whitworth LA, Feler CA. Spina bifida occulta as a relative contraindication for percutaneous retrograde lead insertion for sacral nerve root stimulation. Neuromodulation. 2002;5(1):38-40doi: 10.1046/j.1525-1403.2002._2007.x.
Michael, L. M., Whitworth, L. A., & Feler, C. A. (2002). Spina bifida occulta as a relative contraindication for percutaneous retrograde lead insertion for sacral nerve root stimulation. Neuromodulation : journal of the International Neuromodulation Society, 5(1), 38-40. https://doi.org/10.1046/j.1525-1403.2002._2007.x
Michael, L Madison, et al. "Spina bifida occulta as a relative contraindication for percutaneous retrograde lead insertion for sacral nerve root stimulation." Neuromodulation : journal of the International Neuromodulation Society vol. 5,1 (2002): 38-40. doi: https://doi.org/10.1046/j.1525-1403.2002._2007.x
Michael LM, Whitworth LA, Feler CA. Spina bifida occulta as a relative contraindication for percutaneous retrograde lead insertion for sacral nerve root stimulation. Neuromodulation. 2002 Jan;5(1):38-40. doi: 10.1046/j.1525-1403.2002._2007.x. PMID: 22151780.
Copy Download .nbib Format: NLM
Effect of Potato virus Y on Yield of Three Potato Cultivars Grown Under Different Nitrogen Levels.

Plant disease

Whitworth JL, Nolte P, McIntosh C, Davidson R.
PMID: 30786478
Plant Dis. 2006 Jan;90(1):73-76. doi: 10.1094/PD-90-0073.

Previous studies have shown that Potato virus Y (PVY) reduces yield in many cultivars. Typical foliar symptoms can include veinal necrosis, leaf drop, and a mosaic pattern sometimes accompanied by leaf roughness. Infection by PVY in Russet Burbank produces...

Cite
Whitworth JL, Nolte P, McIntosh C, et al. Effect of Potato virus Y on Yield of Three Potato Cultivars Grown Under Different Nitrogen Levels. Plant Dis. 2006;90(1):73-76doi: 10.1094/PD-90-0073.
Whitworth, J. L., Nolte, P., McIntosh, C., & Davidson, R. (2006). Effect of Potato virus Y on Yield of Three Potato Cultivars Grown Under Different Nitrogen Levels. Plant disease, 90(1), 73-76. https://doi.org/10.1094/PD-90-0073
Whitworth, Jonathan L, et al. "Effect of Potato virus Y on Yield of Three Potato Cultivars Grown Under Different Nitrogen Levels." Plant disease vol. 90,1 (2006): 73-76. doi: https://doi.org/10.1094/PD-90-0073
Whitworth JL, Nolte P, McIntosh C, Davidson R. Effect of Potato virus Y on Yield of Three Potato Cultivars Grown Under Different Nitrogen Levels. Plant Dis. 2006 Jan;90(1):73-76. doi: 10.1094/PD-90-0073. PMID: 30786478.
Copy Download .nbib Format: NLM
Antioxidant Therapy in Parkinson's Disease: Insights from .

Antioxidants (Basel, Switzerland)

De Lazzari F, Sandrelli F, Whitworth AJ, Bisaglia M.
PMID: 31936094
Antioxidants (Basel). 2020 Jan 07;9(1). doi: 10.3390/antiox9010052.

Reactive oxygen species (ROS) play an important role as endogenous mediators in several cellular signalling pathways. However, at high concentrations they can also exert deleterious effects by reacting with many macromolecules including DNA, proteins and lipids. The precise balance...

Cite
De Lazzari F, Sandrelli F, Whitworth AJ, et al. Antioxidant Therapy in Parkinson's Disease: Insights from . Antioxidants (Basel). 2020;9(1)doi: 10.3390/antiox9010052.
De Lazzari, F., Sandrelli, F., Whitworth, A. J., & Bisaglia, M. (2020). Antioxidant Therapy in Parkinson's Disease: Insights from . Antioxidants (Basel, Switzerland), 9(1), . https://doi.org/10.3390/antiox9010052
De Lazzari, Federica, et al. "Antioxidant Therapy in Parkinson's Disease: Insights from ." Antioxidants (Basel, Switzerland) vol. 9,1 (2020). doi: https://doi.org/10.3390/antiox9010052
De Lazzari F, Sandrelli F, Whitworth AJ, Bisaglia M. Antioxidant Therapy in Parkinson's Disease: Insights from . Antioxidants (Basel). 2020 Jan 07;9(1). doi: 10.3390/antiox9010052. PMID: 31936094; PMCID: PMC7023233.
Copy Download .nbib Format: NLM
Glucocorticoid-induced hypertension and the nitric oxide system.

Expert review of endocrinology & metabolism

Ong SL, Whitworth JA.
PMID: 30780842
Expert Rev Endocrinol Metab. 2012 May;7(3):273-280. doi: 10.1586/eem.12.19.

Glucocorticoid hormones, both naturally occurring and synthetic, have long been recognized as a major cause of hypertension. There are well-described experimental models of glucocorticoid-induced hypertension, such as adrenocorticotropic hormone- and dexamethasone-induced hypertension in rats, although the exact mechanism of...

Cite
Ong SL, Whitworth JA. Glucocorticoid-induced hypertension and the nitric oxide system. Expert Rev Endocrinol Metab. 2012;7(3):273-280doi: 10.1586/eem.12.19.
Ong, S. L., & Whitworth, J. A. (2012). Glucocorticoid-induced hypertension and the nitric oxide system. Expert review of endocrinology & metabolism, 7(3), 273-280. https://doi.org/10.1586/eem.12.19
Ong, Sharon Lh, and Whitworth, Judith A. "Glucocorticoid-induced hypertension and the nitric oxide system." Expert review of endocrinology & metabolism vol. 7,3 (2012): 273-280. doi: https://doi.org/10.1586/eem.12.19
Ong SL, Whitworth JA. Glucocorticoid-induced hypertension and the nitric oxide system. Expert Rev Endocrinol Metab. 2012 May;7(3):273-280. doi: 10.1586/eem.12.19. PMID: 30780842.
Copy Download .nbib Format: NLM
Comment on "mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than .

Autophagy

Ganley IG, Whitworth AJ, McWilliams TG.
PMID: 33818280
Autophagy. 2021 Dec;17(12):4477-4479. doi: 10.1080/15548627.2021.1907269. Epub 2021 Apr 05.

No abstract available.

Cite
Ganley IG, Whitworth AJ, McWilliams TG. Comment on "mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than . Autophagy. 2021;17(12):4477-4479doi: 10.1080/15548627.2021.1907269.
Ganley, I. G., Whitworth, A. J., & McWilliams, T. G. (2021). Comment on "mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than . Autophagy, 17(12), 4477-4479. https://doi.org/10.1080/15548627.2021.1907269
Ganley, Ian G, et al. "Comment on "mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than ." Autophagy vol. 17,12 (2021): 4477-4479. doi: https://doi.org/10.1080/15548627.2021.1907269
Ganley IG, Whitworth AJ, McWilliams TG. Comment on "mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than . Autophagy. 2021 Dec;17(12):4477-4479. doi: 10.1080/15548627.2021.1907269. Epub 2021 Apr 05. PMID: 33818280.
Copy Download .nbib Format: NLM
Real-time Optical Dimensional Metrology via Diffractometry for Nanofabrication.

Scientific reports

Whitworth GL, Francone A, Sotomayor-Torres CM, Kehagias N.
PMID: 32214137
Sci Rep. 2020 Mar 25;10(1):5371. doi: 10.1038/s41598-020-61975-3.

Surface patterning technologies represent a worldwide growing industry, creating smart surfaces and micro/nanoscale device. The advent of large-area, high-speed imprinting technologies has created an ever-growing need for rapid and non-destructive dimensional metrology techniques to keep pace with the speed...

Cite
Whitworth GL, Francone A, Sotomayor-Torres CM, et al. Real-time Optical Dimensional Metrology via Diffractometry for Nanofabrication. Sci Rep. 2020;10(1):5371doi: 10.1038/s41598-020-61975-3.
Whitworth, G. L., Francone, A., Sotomayor-Torres, C. M., & Kehagias, N. (2020). Real-time Optical Dimensional Metrology via Diffractometry for Nanofabrication. Scientific reports, 10(1), 5371. https://doi.org/10.1038/s41598-020-61975-3
Whitworth, Guy L, et al. "Real-time Optical Dimensional Metrology via Diffractometry for Nanofabrication." Scientific reports vol. 10,1 (2020): 5371. doi: https://doi.org/10.1038/s41598-020-61975-3
Whitworth GL, Francone A, Sotomayor-Torres CM, Kehagias N. Real-time Optical Dimensional Metrology via Diffractometry for Nanofabrication. Sci Rep. 2020 Mar 25;10(1):5371. doi: 10.1038/s41598-020-61975-3. PMID: 32214137; PMCID: PMC7096422.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 131 entries